Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (352)	3/31/2002 11:58:22 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 557

xcyte.com Tgen probably doesn't have enough cash to play around with CellExSys and "REM", although they hype it a bit on their website here: targen.com With a lot of biotech valuations in the toilet, the average shareholder in something like Tgen, has got to be feeling like a sucker. So, when Xcyte has its IPO, you can be sure I wont be helping to ensure the VCs get a return on their investment. Fool me twice! <g>. Xcyte Therapies has raised over $60 million from leading venture capital firms including: ARCH Venture Partners MPM Capital The Sprout Group Alta Partners Tredegar Investments Vulcan Northwest China Development Industrial Bank Sofinnova Vector Fund Management Falcon Technology Partners Fluke Capital Management CDIB Biotech USA Investment Company MGN Opportunity Group